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Neuroprotective treatments in Parkinson’s disease (PD) have remained elusive. Psychotropics are commonly prescribed in PD
without regard to their pathobiological eﬀects. The authors investigated the eﬀects of psychotropics on pathobiological proteins,
proteasomal activity, mitochondrial functions, apoptosis, neuroinﬂammation, trophic factors, stem cells, and neurogenesis. Only
ﬁndings replicated in at least 2 studies were considered for these actions. Additionally, PD-related gene transcription, animal
model, and human neuroprotective clinical trial data were reviewed. Results indicate that, from a PD pathobiology perspec-
tive, the safest drugs (i.e., drugs least likely to promote cellular neurodegenerative mechanisms balanced against their likelihood
of promoting neuroprotective mechanisms) include pramipexole, valproate, lithium, desipramine, escitalopram, and dextro-
methorphan. Fluoxetine favorably aﬀects transcription of multiple genes (e.g., MAPT, GBA, CCDC62, HIP1R), although it
and desipramine reduced MPTP mouse survival. Haloperidol is best avoided. The most promising neuroprotective investigative
prioritieswill involve disease-modifying trials of the safest agents alone or in combination to capture salutaryeﬀects on H3histone
deacetylase, gene transcription, glycogen synthase kinase-3, α-synuclein, reactive oxygen species (ROS), reactive nitrogen species
(RNS), apoptosis, inﬂammation, and trophic factors including GDNF and BDNF.
1.Introduction
Parkinson’s disease (PD) and other neurodegenerative dis-
eases are common and impose substantial morbidities and
costs on patients, caregivers, and society [1–3]. Neuropsy-
chiatric conditions occur in most patients with Parkinson’s
disease (PD), with 61–88% of patients reporting at least one
psychiatricsymptom [2]. Neuropsychiatric disorders include
a variety of cognitive concerns, delirium, dementia, depres-
sion, anxiety, panic, and other conditions related either
to PD itself or its treatment [2]. These neuropsychiatric mor-
bidities are quite signiﬁcant, with cognitive impairment and
depression constituting two of the strongest determinants of
PD quality of life [2]. As such, these conditions necessitate
treatment.
Psychotropics are commonly used to treat these PD co-
morbidities without regard to their potential pathobiological
eﬀects[3,4].Furthermore,psychotropicsareusedintreating
the dementias that attend PD (Parkinson’s disease demen-
tia, dementia with Lewy bodies, and Alzheimer’s disease),
eventually present in nearly all patients [1, 2]. Addition-
ally, dopaminergic therapies (levodopa, dopamine agonists)
and deep brain stimulation are associated with treatment
complications including mania, gambling, hypersexuality,
other impulse control disorders, and suicide attempts [2].
Psychotropics are widely prescribed for these conditions,
again without considering their potential disease-modifying
eﬀects.
Psychotropics can directly [3] and indirectly [4]a ﬀect
neurodegenerative pathobiology in a variety of ways [3, 4].2 Parkinson’s Disease
Forexample,adrugcandirectlyaﬀectapoptoticmechanisms
and/or can indirectly aﬀect apoptosis by its direct eﬀects
on pathogenic proteins, the proteasome, mitochondria, free
radical formation, microglial activation, or inﬂammation
[4]. Previous work had considered the eﬀects of psychotrop-
ics on intracellular processes including proteins, proteasome,
mitochondrion, and apoptosis [3], supplemented by a wider
array of extracellular actions including neuroinﬂammation,
trophic factors, neural and glial stem cells, and neurogenesis
[4] across various cell types and models [3, 4]. The potential
to modify the course of a neurodegenerative disease through
these eﬀects holds substantial implications for both PD
patients and society as a whole [3, 5]. Figures 1 and 2 depict
the relations and interrelations of these pathobiological
mechanisms in regard to the viability of dopamine neurons.
Psychotropics may also aﬀect the transcription of genes
relevant to PD. The authors were therefore interested in
exploring the eﬀects of psychotropic drugs on each of these
intracellular domains in published medical literature and
gene expression databases. In this paper, we provide an
update focusing on neuronal neurodegenerative mechanism
ﬁndings that have been replicated in mature neural tissues
or demonstrated in disease-relevant animal models. Second,
as u r v e yo fp s y c h o t r o p i ce ﬀects on the mRNA expression of
genes relevant to PD risk and pathobiology was undertaken.
Since genetic studies have revealed genes associated with
PD risk and certain mutations are associated with various
PD phenotypes, the ability of psychotropics to aﬀect gene
expression could potentially modify the course of PD with
either deleterious or therapeutic potential. Third and ﬁnally,
we consider the extant clinical trial literature as it pertains to
ﬁrst-line psychotropics and neuroprotection in PD.
2.MaterialsandMethods
2.1. Gene Expression Search. We comprehensively survey-
ed gene expression as a function of psychotropic treat-
ment for genes associated with PD risk [6] and the classical
PARK1-13 mutations associated with PD [7]a n d
PARK14–16 by assessing literature in the PubMed (http://
www.ncbi.nlm.nih.gov/pubmed) and Gene Expression
Omnibus Proﬁles (GEO Proﬁles http://www.ncbi.nlm.nih.
gov/sites/entrez?db=geo) databases. Risk-associated genes
consisted of the genes most strongly associated with PD
according to the PDGene database [6]. These genes were
SNCA, MAPT/STH, NUCKS1, PM20D1, SLC41A1, BST1,
LRRK2, USP24, SLC6A3, GBA, SLC45A3, SOD2, MTHFR,
PLEKHM1, DGKQ, BDNF, PDXK, GWA 7p14.2, APOE,
DRD3, GWA 2q36.3, GSTM1, PINK1, FGF20, CYP2D6,
PARK2(parkin),HLA-DRA,GLIS1,MAOB,CALB1,FARP1,
LRP8, DRD2, UCHL1, GAK, MCCC1/LAMP3, STK39,
SYT11, HLA-DRB5, CCDC62/HIP1R, ACMSD, and
MED13. PARK 1–16 genes were also surveyed.
Drugs considered included ﬁrst-line direct-acting D2/D3
dopamine agonists, antipsychotics, mood stabilizers, antide-
pressants, anxiolytics, and dextromethorphan combined
with quinidine. While a primary treatment for the under-
lying disease, D2/D3 dopamine agonists are also used to
treat apathy and have antidepressant qualities and were
therefore included in this paper. Drugs were searched by
their psychopharmacological category and by their speciﬁc
names in each database. Speciﬁc drug search terms used
were “neuroleptic OR atypical antipsychotic OR antipsy-
chotic OR anxiolytic OR benzodiazepine OR antidepressant
OR tricyclic antidepressant OR heterocyclic antidepressant
OR SSRI OR selective serotonin reuptake inhibitor OR
pramipexole OR ropinirole OR amantadine OR haloperidol
OR ﬂuphenazine OR triﬂuoperazine OR thiothixene OR
chlorpromazine OR thioridazine OR risperidone OR olan-
zapine OR quetiapine OR ziprasidone OR aripiprazole OR
clozapine OR paliperidone OR iloperidone OR asenapine
OR tetrabenazine OR pimavanserin OR lithium OR car-
bamazepine OR oxcarbazepine OR valproate OR lamot-
rigine OR amitriptyline OR imipramine OR nortriptyline
OR desipramine OR clomipramine OR trimipramine OR
doxepinORprotriptylineORmaprotilineORbupropionOR
ﬂuoxetine OR sertraline OR ﬂuvoxamine OR paroxetine OR
citalopram OR s-citalopram OR trazodone OR nefazodone
OR venlafaxine OR duloxetine OR mirtazapine OR atomox-
etine OR buspirone OR diazepam OR chlordiazepoxide OR
ﬂurazepam OR temazepam OR clorazepate OR clonazepam
OR lorazepam OR oxazepam OR alprazolam OR zaleplon
OR zolpidem OR zopiclone OR s-zopiclone OR cyprohepta-
dine OR hydroxyzine OR diphenhydramine OR benztropine
OR trihexyphenidyl OR modaﬁnil OR ramelteon OR dex-
tromethorphan OR quinidine.” Levodopa was not reviewed
because it generally is not prescribed to treat behavioral
problems. Cognitive enhancers (cholinesterase inhibitors
and NMDA antagonists) are not reviewed here because they
haveanextensiveliteraturethathasbeenreviewedelsewhere.
The term “AND (mRNA OR gene expression)” was added to
gene names, symbols, aliases, and drug terms in PubMed. A
varietyofmodelsandtreatmentdurationswereencountered.
Because psychotropics tend to be administered chronically
in the clinical treatment of PD, only reports of chronic
administration (at least 3-week duration in animal studies)
are considered here.
Gene expression data in GEO Proﬁles was considered if
a given treatment was compared to untreated controls under
the same experimental conditions and if the data involved
at least 2 determinations at a single locus (solitary deter-
minations can be unreliable). Gene expression data in GEO
Proﬁles were found for the selective serotonin reuptake
inhibitor (SSRI) antidepressant ﬂuoxetine, the neuroleptic
antipsychotic haloperidol, and the atypical antipsychotics
olanzapine and clozapine. Fluoxetine was administered for
21 days in mice, and gene expression was determined relative
to untreated controls in the hippocampus (GEO Proﬁles
accession number GDS2803) using the Aﬀymetrix Gene
ChipR Mouse Genome 430 2.0 Array [8]. Olanzapine was
given for 21 days in rats, and gene expression was compared
to untreated controls in the frontal cortex (accession number
GDS2608) using the Aﬀymetrix Gene ChipR Rat Genome
230 2.0 Array [9]. Results for haloperidol and clozapine rela-
tivetountreatedcontrolmicereﬂectgeneexpressioninbrain
after treatment for 4 weeks (accession number GDS2537)
using the Aﬀymetrix Gene ChipR Murine Genome U74Parkinson’s Disease 3
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Figure 1: Factors aﬀecting the viability of dopamine neurons. Relations terminating in an arrowhead indicate facilitation, those with double
arrowheads indicate mutual facilitation, and dashed lines terminating in a bulb indicate inhibition. Though still being settled, recent data
suggest that alpha-synuclein (αSyn) is neuroprotective whereas monoubiquitylated αSyn, aggregated αSyn, and other pathogenic proteins
promote neurodegeneration. H3 histone deacetylase inhibition (HDACI) increases αSyn, brain derived neurotrophic factor (BDNF),
and glial derived neurotrophic factor (GDNF), supporting neuronal synapses (αSyn) and providing trophic support for neurons and
promoting neurogenesis (BDNF and GDNF). Neurotrophism appears to be facilitated by D3 dopamine receptor stimulation. HDACI also
inhibits inﬂammation. Aggregated proteins inhibit the proteasome, promote reactive oxygen species (ROS), mitochondrial dysfunction,
inﬂammation, and apoptosis, and impair neuronal viability. Inhibition of the proteasome results in reduced elimination of obsolete
proteins, increases in aggregated protein species, facilitates apoptosis, and impairs neuronal viability. N-methyl-D-aspartate (NMDA)
receptor activation by glutamate promotes neurotoxicity and apoptosis. Generation of peroxide radicals by MAOB promotes ROS. ROS and
inﬂammationmutuallypromoteeachother,andeachcaninduceapoptosis.MitochondrialdysfunctionandROSalsomutuallypromoteeach
other.Impairedmitochondrialrespirationthroughinhibitionofrespiratorychaincomplexes(I-IV)canproducemitochondrialdysfunction.
Mitochondrial dysfunction leads to the loss of the mitochondrial membrane potential, opening of the mitochondrial permeability transition
pore, and the release of cytochrome c and apoptosis inhibiting factor (AIF). Cytochrome c and AIF each independently trigger apoptosis.
Protective factors against neurodegeneration include GBA, DRD3, CALB1, and other gene products. Thus, neurodegenerative processes
includepathogenicproteins,proteasomaldysfunction,glutamateandothertoxicmolecules,NMDAreceptoractivation,ROS,mitochondrial
dysfunction, apoptotic pathway activation, and subsequent neuroinﬂammation, in turn potentially inducing further ROS and apoptosis.
Neuroprotective factors include GBA, MCCC1,CCDC62, HIP1R, DRD3, CALB1, αSyn, HDACI, BDNF, and GDNF. Neuroprotective factors
promote while neurodegenerative processes impair the viability of the dopamine neuron. Nigral dopamine neurons promote normal motor
functioning by release of dopamine on striatal D2 receptors, transcribed from the DRD2 gene, and reduced D2 stimulation is associated with
Parkinson motor features.
Version 2 Array [MG U74Av2] and 12 weeks (accession
number GDS2531) using the Aﬀymetrix Gene ChipR Mouse
Expression 430A Array [MOE430A]. Investigations were
limited to murine species in GEO Proﬁles, and no studies of
gene expression in the substantia nigra or striatum were en-
countered.
Reporting of GEO Proﬁles ﬁndings is limited to genes
where speciﬁc probe sets were upregulated or downregulated
by at least 20%. Percentage change for a given reporter probe
setwascalculatedasthediﬀerenceofthereporterprobevalue
for treated animals from its untreated control values divid-
ed by that control value. In cases where there were positive
ﬁndings for any gene probe set, probe sets were assessed to
determine their reliability in assaying gene expression.
Results are provided for genes for which changes in expres-
sion were observed after considering probe set reliability.
Normalized expression data in GEO Proﬁles were derived
from a gene chip and remain to be conﬁrmed by quantitative
real-time polymerized chain reaction (RT-PCR) or other
analyses.
2.2. Posttranscriptional Neurodegenerative Mechanisms
Search. Relevant studies were identiﬁed through a literature
search of intracellular and extracellular neurodegenerative
mechanisms (PubMed search terms: (alpha-synuclein OR
beta-amyloid OR tau OR TDP-43 OR ubiquitin OR prot-
easome OR mitochondrial viability OR mitochondria OR
mitochondrial transition pore OR cytochrome c release OR
endosome OR lysosome OR autophagy OR endoplasmic re-
ticulum OR leukocyte viability OR apoptosis OR inﬂam-
mation OR trophins OR neurogenesis OR BDNF OR GDNF
OR neural stem cells) AND (neuron OR neuronal OR4 Parkinson’s Disease
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Figure 2: Interactions of neuroprotective and neurodegenerative pathways emphasizing pathogenic proteins and toxins. Relations ter-
minating in an arrowhead indicate facilitation, those with double arrowheads indicate mutual facilitation, whereas dashed lines terminating
in a bulb indicate inhibition. The enzyme glycogen synthase kinase 3 beta (GSK-3β) activates glutamatergic excitotoxicity mediated through
the N-methyl-D-aspartate (NMDA) receptor. GSK-3β also drives production of alpha-synuclein (αSyn), the pathogenic proteins beta-
amyloid (Aβ) and tau, and apoptosis. Whereas αSyn appears to be neuroprotective and inhibits apoptosis, mono-ubiquitylated αSyn
promotes αSyn aggregation and apoptosis. On the other hand, αSyn can also increase GSK-3β and tau concentrations, in turn increasing
aggregated αSyn, Aβ, and tau itself. Tau can further increase concentrations of αSyn. Aggregated αSyn, Aβ, and tau inhibit the proteasome
and induce cellular toxicity, reactive oxygen species (ROS), mitochondrial dysfunction, apoptosis, and inﬂammation, leading to neuronal
demise.Thethreeproteinspromotetheformationof each other,asdotheiraggregated forms.TheLRP8geneproductstabilizes microtubule
associated protein tau (MAPT), the gene that produces tau protein, and dysfunctional LRP8 leads to excessive MAPT expression, increasing
tau and driving pathogenic protein aggregation. Pathogenic proteins are disposed of through autophagy and the ubiquitin-proteasomal
system, wherein proteins targeted for destruction are polyubiquitylated, a process that appears to be regulated by PARK5 (UCHL1) and
PARK2 (parkin). Interference with autophagy or ubiquitylation prevents disposal of proteins, leading to their accumulation and their
subsequent inhibition of the proteasome. GSTM1 and CYP2D6 gene products promote solvent detoxiﬁcation, and deﬁciencies in these
proteins permit toxicity. GSTM1 is particularly important in the context of CYP2D6 dysfunction.
neurons OR glia OR glial OR neuroglia)). These terms were
joined by the operator “AND” to the drug search terms de-
tailed in the gene expression section, except that only the
speciﬁcdrugslistedweresearched(thepharmacologicalclass
searchtermswereomitted,speciﬁcally“neurolepticORatyp-
ical antipsychotic OR antipsychotic OR antidepressant OR
anxiolytic OR benzodiazepine OR antidepressant OR tri-
cyclic antidepressant OR heterocyclic antidepressant OR
SSRI OR selective serotonin reuptake inhibitor”).
Citations were reviewed with an exclusive focus on ma-
ture neural tissues because nonneural, immature neural tis-
sues and malignancy-related cells lines have been demon-
strated to behave diﬀerently with regard to the processes
studied here. The sole exception occurred in disease-speciﬁc
animal models, where stem cells in mature brain were also
considered. We considered studies of any methodology but
included only models relevant in PD (including PD-speciﬁc
models and results involving cells or biological processes
speciﬁcally relevant to PD). Thus, cell culture conditions not
typical of PD (e.g., hyperosmotic stress, oxygen deprivation,
potassium deprivation, etc.) were also excluded.
We focused on the intracellular processes of interest as
speciﬁed in the search terms and did not consider studies of
other mechanisms unless those studies also considered the
targeted processes. For example, intracellular calcium inﬂux
and other disease mechanisms were not examined unless
theyalsoinvolvedthedrugsandprocessesofinterest.Deoxy-
ribonucleic acid (DNA) fragmentation and condensation
were required to ascertain apoptosis, and other indices (apo-
ptoticmediatorconcentration,cellviability)wereconsidered
insuﬃcient.
In contrast, in disease-speciﬁc animal models, outcomes
consistent with putative neuroprotection were considered
even if the study did not speciﬁcally address the intracellularParkinson’s Disease 5
targets required for cell and tissue studies, provided that the
outcomes were relevant to PD-speciﬁc clinical outcomes. We
considered studies in rotenone, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), lipopolysaccharide (LPS), and
other rodent PD models, a transgenic mouse model relevant
to tauopathic parkinsonism (FTDP-17, or frontotemporal
dementia with parkinsonism related to tau mutations on
chromosome 17), and an amyotrophic lateral sclerosis (ALS)
mouse model that examined alpha-synuclein (αSyn).
2.3. Neuroprotective Clinical Trials Search. Clinical studies
potentially relevant to determining disease-modifying neu-
roprotection of drugs in PD, especially those employing neu-
rodegenerative laboratory measures, representing ﬁrst-line
psychotropics were identiﬁed through a literature search and
bibliographic extension across the literature (PubMed search
terms: (neuroprotection OR neuroprotective OR disease
modifying OR disease modifying OR disease modiﬁcation
OR progression OR disease progression OR biomarker OR
alpha-synuclein OR cerebrospinal ﬂuid OR imaging OR
magnetic resonance imaging OR single photon emission
computed tomography OR positron emission tomography)
AND Parkinson’s disease). These terms were joined by the
operator“AND”tothedrugsearchtermsspeciﬁedinthesec-
tion “Posttranscriptional Neurodegenerative Mechanisms
Search.”
3. Results andDiscussion
Chronic psychotropic treatment had some noteworthy
eﬀects on the mRNA transcription of PD risk-related genes.
Forthesakeofbrevity,genemRNAexpressionﬁndingsmen-
tioned below generally do not include negative chronic (i.e.,
atleast3weeks)treatmentstudiesunlessthenegativeﬁnding
is speciﬁcally pertinent to the nigrostriatal tract.
Several genes are highly associated with risk (P<
0.000001), mentioned here in order of strongest to weakest
association with PD risk. It is important to keep in mind that
the rank ordering of associated genes can change over time
as more data are reported. MAPT (this gene’s oﬃcial
designation)islocatedatq21.1onchromosome17(17q21.1)
and is the gene for microtubule-associated protein tau. It has
the strongest association with PD risk of all genes. Increased
promoter region function, especially with the H1 haplotype,
isassociatedwithlate-onsetPD.TauandαSynproteinsinter-
act to mutually promote their synthesis and aggregation (see
LithiumandValproatesectionsbelow).GBAencodesforacid
beta-glucosidase (1q21), mutations of which are linked to
PD through an obscure mechanism. MCCC1 (3q27) is the
gene for methylcrotonoyl-coenzyme A carboxylase 1 alpha.
This protein is involved in nucleotide binding, catalytic acti-
vity, ATP binding, biotin binding, and ligase activity and
is found in Golgi apparatus and the mitochondrial matrix
and inner membrane. Deﬁciency impairs leucine degrada-
tion and produces an organic acidemia with neurological
features. CCDC62/HIP1R (12q24.31/12q24) involves two
diﬀerentgenes.Coiled-coildomaincontaining62(CCDC62)
is involved with estrogen receptor activation, cyclin D1
expression, and cell growth in prostate cancer, and anti-
bodies to this protein develop in various malignancies. This
suggests that CCDC62 may play a role in augmenting cell-
ular viability, but its true role in PD awaits discovery. Hunti-
ngtin-interacting protein 1-related (HIP1R) is involved in
actin binding and receptor-mediated endocytosis. Loss of
function is associated with impaired presynaptic function
and plasticity, leading to neuronal dysfunction. It appears to
protect against polyglutamine toxicity in the transgenic C.
elegans Huntington model.
Genes less strongly associated with PD risk include
BDNF (11p13), the translation of which produces brain-
derived neurotrophic factor. BDNF is critical to the survival
of striatal neurons. A rare functional G196A (Val66Met)
BDNF variant is associated with greater PD severity, earlier
PD onset, and cognitive impairment. DRD3 (3q13.3) is the
gene for the D3 dopamine receptor. Reduced lymphocyte
DRD3 mRNA and the DRD3 2 allele are associated with PD.
GSTM1 (1p13.3) encodes glutathione S-transferase mu 1
and is involved in detoxifying electrophilic compounds. The
GSTM1 null genotype is linked to PD in the contexts of
CYP2D6 poor metabolizer status and solvent exposure.
PARK2 (parkin, 6q25.2-q27) mutations are classicallyassoci-
ated with sporadic PD and with recessive, early-onset, slowly
progressive, Lewy body-negative parkinsonism. Parkin is an
E3 ubiquitin ligase enzyme of the ubiquitin-proteasome
system, key to disposing of obsolete and toxic proteins.
Additionally, parkin confers resistance to oxidative mito-
chondrial damage and to various apoptogenic stimuli.
MAOB (Xp11.23) translation produces monoamine oxidase
B.TheMAOBGgenotypeisvariablyassociatedwithreduced
PD risk in Caucasian but not Asian men. CALB1 (8q21.3-
q22.1) is the gene for the 28 kilo-Dalton calbindin 1. The
CALB1 SNP rs1805874 is linked to PD risk through an
unclear mechanism. LRP8 (1p34) is the gene for low-density
lipoprotein receptor-related protein 8, associated with the
apolipoprotein E receptor. LRP8 knockout increases tau
phosphorylation in mice suggesting a relation to MAPT (see
above). DRD2 (11q23) encodes the D2 dopamine receptor.
Knockout in mice produces parkinsonism, and the TaqIa
polymorphism, especially the A1A1 genotype, and 15-allele
polymorphism are associated with PD motor ﬂuctuation
risk. DRD2-deﬁcient mice manifest akinesia and bradyki-
nesia resembling PD. PARK5 (UCHL1, 4p14) mutations
are classically associated with PD onset in the 6th decade.
UCHL1 is involved in maintaining ubiquitin monomers
for proper functioning of the ubiquitin-proteasome system
and has the weakest association with PD risk of the genes
considered here. Figures 1 and 2 show the relationship of
these genes to the pathobiological processes involved in PD.
For each drug, available ﬁndings for gene expression,
replicated posttranslational ﬁndings (largely cell culture),
andanimalmodelsarepresented.Thegeneexpressioneﬀects
of psychotropics are considered for PD risk without regard
to particular mutations, variants, and genotypes, which are
beyond the scope of this paper. It is possible that reduced
risk may also translate to slower PD progression, although
correlates of risk and disease progression often diﬀer.
Replicated ﬁndings mostly involved cell culture, with the6 Parkinson’s Disease
majority replicated across models (almost half of these inde-
pendently replicated), and nearly half replicated within the
same model (only valproate induction of αSyn was indepen-
dently replicated). Independent replication within and with-
out models was only evident for lithium and valproate, con-
stituting the two most robustly replicated preclinical ﬁnd-
ings. Findings from animal models are then detailed. Most
PD animal model studies of psychotropics have shown
neuroprotective results, including pramipexole, lithium, val-
proate, lamotrigine, and dextromethorphan, in contrast to
desipramine and ﬂuoxetine, which actually shortened mouse
survival.
Finally, following the presentation of transcriptomics,
cell culture, and animal model ﬁndings, clinical trials of
drugs constituting ﬁrst-line psychotropics in human patients
with PD are discussed.
3.1. Pramipexole. In the rotenone mouse model of PD, this
dopamine D2/D3 receptor agonist decreased αSyn, neuronal
death,andmotordeﬁcits[10].IntheMPTPratmodelofPD,
pramipexole inhibited reactive oxygen species (ROS) genera-
tion [11]. In the LPS rat model of PD, pramipexole preserved
dopamine neurons and reduced ubiquitin upregulation and
amphetamine-induced ipsiversive turning, but did not aﬀect
the inﬂammatory response [12]. In a 6-hydroxydopamine
rat model of PD, pramipexole increased cell proliferation
and survival, neural diﬀerentiation, neurogenesis, and epi-
dermal growth factor mRNA in the subventricular zone and
increased motor activity [13]. This drug has also increased
both BDNF and glial-derived neurotrophic factor (GDNF)
in mesencephalic and nigral astrocytic cell culture [14]. Each
of these actions is consistent with a reduced risk of PD
progression.
3.2. Ropinirole. Although this D2/D3 agonist has been
demonstrated to be antiapoptotic in neuroblastoma cell
lines, evidence in mature neural tissues was not evident. This
drug, however, has been associated with increases in both
BDNF and GDNF in rat mesencephalic cell and nigral
astrocytic cultures, but not in striatal or cortical astrocytic
culture [14]. In a study of mouse astrocytes taken from
whole brain, ropinirole increased GDNF but not BDNF [15].
Ropinirole’s neurotrophic eﬀect on cultured mesencephalic
dopamine neurons was inhibited by the D3 antagonist
nafadotride [14]. These ﬁndings suggest neurorestorative
eﬀects of this drug.
3.3. Antipsychotics. Although it would be ideal to have stud-
ies conducted in blood and brain of patients with PD, no
suchstudieshavebeenreported,andthebestdatathatcanbe
obtained for the transcriptional eﬀects of psychotropics has
been determined in patients with psychiatric disorders.
Chronic antipsychotic treatment downregulated LRP8 and
UCHL1(PARK5)expressioninschizophrenia[16,17].Anti-
psychotic administration downregulated ApoER2 (LRP8)
mRNA in peripheral lymphocytes after 6 months of treat-
ment compared to pretreatment baseline in drug-naive
patients with schizophrenia [16]. In postmortem prefrontal
cortex,chronictreatmentwasassociatedwithdownregulated
UCHL1 mRNA relative to matched healthy controls and
drug-na¨ ıve patients [17]. Since reductions in LRP8 and
UCHL1 function are linked to PD, the eﬀects of antipsy-
chotics in these studies would be expected to increase PD
risk and, possibly, PDprogression (seeFigure 2forLRP8and
P A R K 5r e l a t i o nt oP Dp a t h o b i o l o g y ) .
3.4. Neuroleptics. Neuroleptic inhibition of mitochondrial
respiratory Complex I in frontal cortex has been replicated
[18, 19], suggesting an increased risk of PD progression and,
perhaps, an increased risk of developing the disease.
3.5. Chlorpromazine. Six-month treatment with chlorpro-
mazine upregulated prefrontal and temporal cortical DRD2
mRNA expression in primates [20], an eﬀect that might
reduce PD risk and progression.
3.6. Haloperidol. Haloperidol treatment is associated with
DRD3, striatal PARK2 (parkin), and striatal DRD2 upreg-
ulation and nonstriatal BDNF downregulation. Four weeks
of haloperidol induced striatal Park2 [21] and whole brain
Drd3 [22, 23] expression in rats, suggesting parkin upregu-
lation speciﬁc to the nigrostriatal system. In rat pituitary, 21
days of haloperidol upregulated D2 mRNA expression [24].
Although early striatal studies were negative in rodents [25–
27],subsequentstudiesfoundupregulatedstriatalD2mRNA
expression changes after chronic haloperidol treatment [23,
28–32]. Four-week administration upregulated striatal and
prefrontal cortical Drd2 expression in rats [22, 32]. In
primates, 6-month treatment with haloperidol also upregu-
lated prefrontal and temporal cortical D2 mRNA expression
[20]. In contrast, haloperidol downregulated hippocampal
and cortical Bdnf expression in rats [33–35], although one
hippocampal study showed no change [36].
The replicated mitochondrial eﬀects of haloperidol
include Complex I inhibition in frontal cortex [18, 19],
Complex II inhibition [37], and apoptosis-inducing factor
(AIF) translocation [38].
In sum, while upregulation of striatal PARK2, DRD3,
and DRD2 might reduce PD risk, BDNF downregulation,
complex I and II inhibition, and AIF translocation would be
expected to increase PD risk and could potentially predomi-
nate, increasing risk and perhaps progression (Figures 1
and 2). Of course, clinical exacerbation of parkinsonian
neurological features eﬀectively contraindicates the use of
clinical doses of haloperidol in PD.
3.7. Loxapine. Loxapine administered for 32 days upregu-
lated whole brain D3 [22, 23] and D2 [22, 32]m R N Ai n
rats, thus suggesting an association of loxapine with PD risk
reduction.
3.8. Molindone. Six-month treatment with molindone
upregulated prefrontal and temporal cortical D2 mRNA
expression in primates [20], a ﬁnding that is consistent with
a potentially reduced PD risk.
3.9. Pimozide. Pimozide upregulated whole brain D3 mRNA
in rats after 32 days [22] and upregulated prefrontal and
temporal cortical D2 mRNA expression in primates after 6
months [20], suggesting a lowering of PD risk.Parkinson’s Disease 7
3.10.Risperidone. Risperidone[39,40]treatmentfor4weeks
in rats upregulated frontal cortical Maob expression while
6-month treatment upregulated prefrontal and temporal
cortical D2 mRNA expression in primates [20]. The D2
result is consistent with a potentially reduced risk for PD. In
contrast, risperidone inhibition of frontal cortical Complex
I has been replicated, suggesting an increased risk of PD
progression [18].
3.11. Olanzapine. Olanzapine upregulated hippocampal and
cortical Bdnf [34], frontal cortical Gstm1 [9]a n dM a o b
[40], and ventral tegmental Drd2 [41] expression in rats,
collectively indicative of reduced PD risk (Figures 1 and 2).
Similarly, 6-month treatment with olanzapine upregulated
prefrontal and temporal cortical D2 mRNA expression in
primates, but in contrast to other drugs, olanzapine did
not aﬀect striatal DRD2 expression [20]. These ﬁndings
nevertheless suggest a lower risk of PD, especially the
tegmental ﬁnding.
3.12. Quetiapine. The rat literature reveals upregulated pre-
frontalcorticalBdnf mRNAwithquetiapine [42],potentially
consistent with reduced PD risk.
3.13. Clozapine. Although rat Bdnf studies reveal both
upregulation [34] and downregulation [35] in the hip-
pocampus and cortex with clozapine (10mg/kg for 28 days)
[34, 35], Drd3 expression was upregulated in whole brain
after32daysoftreatment[22].Six-monthtreatmentupregu-
lated prefrontal and temporal cortical D2 mRNA expression
in primates, but in contrast to the other drugs, clozapine
did not aﬀect striatal DRD2 expression [20]. Nevertheless,
clozapine inhibition of frontal cortical Complex I [18]a n d
increase in Complex IV [19] have been replicated, likely
indicating an increased risk of PD progression in light of
r e d u c e dC o m p l e xIi nP D( Figure 1). Therefore, it is unclear
whether clozapine is associated with a reduced or increased
risk of PD.
3.14.Aripiprazole. Intheventraltegmentalarea,aripiprazole
increased D2 mRNA expression after 12 weeks of treatment
[41], suggesting a reduced risk for PD.
3.15. Lithium. Lithium downregulated BDNF mRNA (while
increasing BDNF itself) [43] and did not aﬀect ventral
tegmental D2 [44] mRNA expression in rats, suggesting
neutral risk for PD. In contrast, replicated ﬁndings were con-
ﬁned to decreases in ﬁbrillar tau in transgenic FTDP-17
models [45, 46] and cytochrome c release [47, 48], each
associated with the likelihood of a neuroprotective reduced
PD progression (Figure 1). In animal models, although in
the G93A superoxide dismutase 1 mutant transgenic mouse
model of ALS, lithium has been found to decrease both
αSyn and ubiquitin aggregation [49]. Although in several
diﬀerent tauopathic FTDP-17 mouse models, lithium de-
creased tau phosphorylation at a variety of epitopes includ-
ing Tau1 [45], Ser202 [50], AT8 [46], and PHF1 [46, 50]
and decreased tau ﬁbrillization [46]a n dﬁ b r i l l a r[ 45]a n d
ﬁlamentous [45] tau aggregation. Human FTDP-17 has been
particularly associated with Ser202 [51]a n dA T 8[ 52]
phosphorylation. These models are not only relevant to
FTDP-17, but potentially also to PD because tau and
αSyn interact to mutually promote their production and
aggregation, as explained below (see also Figure 2). Finally,
lithium prevented nigrostriatal dopamine neuronal loss in
MPTP mice [53]. Each of these ﬁndings is consistent with
a reduced risk of progression in PD.
Eﬀects on other proteins, such as Aβ and tau, are poten-
tially important to the pathobiology of PD. A referenced
discussion is beyond the scope of this paper; however,
we have detailed the interactions of these proteins with
αSyn elsewhere [4]. Brieﬂy, Aβ and tau each facilitate
αSyn aggregation in PD (Figure 2). αSyn also facilitates tau
aggregation, and αSyn and tau each independently initiate
amyloid formation, further facilitating αSyn aggregation.
Furthermore, the enzyme glycogen synthase kinase 3 (GSK-
3) promotes αSyn expression, Aβ production, tau phos-
phorylation, and apoptosis. GSK-3 alleles are associated
with PD risk, and GSK-3 inhibitors including lithium and
valproate may reduce αSyn. Moreover, αSyn upregulates
GSK-3, suggesting that αSyn and GSK-3 mutually upregulate
each other, and αSyn can indirectly upregulate Aβ and tau
production and aggregation through this mechanism. Still
further, each of these proteins (αSyn, Aβ, and tau) can inter-
act at various levels in the pathological chain of events,
leading to apoptotic pathway activation, neuronal death,
and neuroinﬂammation. αSyn, Aβ, and tau each inhibit the
proteasome, impair mitochondrial function, produce free
radicals, and promote apoptosis. Thus, eﬀects on tau and
even Aβ can modulate PD pathobiology. In this regard,
GSK-3 inhibitors, including lithium and valproate, can have
potent eﬀects on αSyn and, potentially, on PD pathobiology
(Figure 2).
3.16. Carbamazepine. Carbamazepine upregulated BDNF
mRNA expression in rat frontal cortex [54], suggesting a
potentially neuroprotective reduced risk of PD.
3.17. Valproate. Replicated ﬁndings include increased αSyn
[55–57] in several models including cell cultures exposed
to 6-hydroxydopamine and glutamate [55, 56] and in the
rotenone rat [57]. Valproate has inhibited apoptosis in
glutamate [55] and rotenone [57] models. Valproate anti-
apoptotically decreased monoubiquitylated αSyn [56, 57]
and its nuclear translocation [56, 57] and inhibited free rad-
ical damage [58]. In the rotenone rat model of PD, valproate
increased αSyn, decreased its apoptotic monoubiquitylation
and nuclear translocation in both the substantia nigra and
striatum, and prevented nigral apoptosis and nigrostriatal
neuronal loss, as well as preventing the death and parkin-
sonian features observed in rotenone rats not treated with
valproate [57]. In addition, valproate both protected and
increased dopaminergic concentrations in rat mesencephalic
mixed neuronal-glial cell cultures after exposures to either
LPS or MPTP [59]. Furthermore, valproate increased BDNF
and GDNF transcription in astrocytic cell cultures [59, 60].
These actions are consistent with neuroprotection, neurore-
generation, and a reduced likelihood of PD progression
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It is noteworthy that, like lithium, valproate too is a
GSK-3 inhibitor. It can therefore potentially produce potent
therapeutic eﬀects on PD pathobiology through attenuation
of αSyn, Aβ, and tau proteins, as detailed in the section
on Lithium (see also Figure 2). Moreover, valproate is also
a histone H3 deacetylase inhibitor (H3 HDACI), and this
action has been correlated with neuroprotective increases
in αSyn levels [61], possibly upregulating the expression
of other risk-attenuating genes while interfering with the
repression of risk-associated genes [57]. (Although the
role of αS y ni nn e u r o d e g e n e r a t i o nh a sb e e ne x t e n s i v e l y
debated and excessive αSyn would seem to predispose to the
formation of Lewy bodies that are associated with PD, recent
evidence suggests a neuroprotective function of the protein
and that it is the depletion of αSyn concentrations and
conversion to a monoubiquitylated species traveling to the
nucleus that instead promotes αSyn ﬁbrillization and neu-
rodegeneration [57]). Additionally, H3 HDACIs including
valproate and dextromethorphan (see Dextromethorphan
section) are protective in MPTP and LPS models and appear
to protect dopamine neurons by upregulating astrocytic
GDNF and BDNF. H3 HDACIs further induce microglial
apoptosis (thereby reducing microglial neuroinﬂammation)
andattenuateLPS-induceddopaminergicneurotoxicity[62],
again like dextromethorphan. Sirtuins are members of
the histone deacetylase family, and inhibition of sirtuin 2
p r o t e c t sc e l l si nP Dm o d e l s[ 63]. Nuclear αSyn has been
shown to inhibit histone acetylation, leading to cellular
demise [64], while HDACIs mediate the opposite action.
Valproate’sGSK-3andH3HDACIpropertiesmayfactorinto
an e u r o p r o t e c t i v ee ﬀect in PD in a signiﬁcant way (Figures 1
and 2).
3.18. Lamotrigine. This anticonvulsant has been conﬁrmed
to reduce striatal lesions by almost 50% in the MPTP
rat model of PD, with an additional 14% reduction when
coadministered with CoQ10 [65], consistent with a neuro-
protective action and reduced risk of PD progression.
3.19. Antidepressants. Findings replicated across antidepres-
sants include neuroprotective decreases in inﬂammatory
cytokine expression, including IL-1β,I L - 6 ,a n dT N F - α [66,
67]; however these same drugs (desipramine and ﬂuoxetine)
also have reduced survival in MPTP mice [68]. An overall
neuroprotective proﬁle for a number of antidepressants
suggests that reduced survival may be unique to the MPTP
model and that the antidepressants hold the potential to
reduce PD progression.
3.20. Amitriptyline. Amitriptyline treatment for at least 21
days in rats upregulated nucleus accumbens shell D3 and
striatal D2 mRNA expression [69], consistent with reduced
PD risk.
3.21. Imipramine. In rats treated for at least 21 days,
imipramineupregulatedhippocampalBdnf[70,71],nucleus
accumbens Drd3 [69], and striatal Drd2 [69] expression,
indicative of reduced risk for PD (Figure 1).
3.22. Desipramine. Desipramine given for 21 days upregu-
latedBdnfinrathippocampus[43,72–74]andfrontalcortex
[74] but, in two studies, downregulated hippocampal mRNA
[75]a n dh a dn oe ﬀect on cortex [43, 75]. Treatment for
at least 21 days upregulated nucleus accumbens shell D3
and striatal D2 mRNA expression [69]. These ﬁndings sug-
gest reduced PD risk with desipramine. Further, decreased
neuronal apoptosis in the context of desipramine treatment
has been replicated [76, 77], suggesting a neuroprotective
diminished risk of PD progression. On the other hand,
desipramine treatment in a MPTP mouse model resulted
in diminished animal survival [68], perhaps unique to this
particular model.
3.23. Nortriptyline. The replication of the ﬁnding that this
tricyclic antidepressant decreased neuronal apoptosis [76,
78] indicates a neuroprotective potential to reduce PD
progression.
3.24. Fluoxetine. Fluoxetine administered for 21 days upreg-
ulated Gba, Ccdc62, Hip1R, Bndf, and Uchl1 and down-
regulated Mapt, Mccc1, Gstm1, and Calb1 expression in rat
frontal cortex [8]. In other rat studies of this antidepressant,
this same treatment course upregulated Bndf mRNA in
frontal cortex and hippocampus [74, 79] (although without
eﬀect in one hippocampal study [75]) and in ventral
tegmental area and nucleus accumbens shell but not in
substantia nigra or striatum [79]. Fluoxetine treatment for
at least 21 days upregulated nucleus accumbens shell Drd3
but not striatal Drd2 expression in rats [69]. Overall, the
ﬁndings suggest a reduced risk of PD (Mapt, Gba, Ccdc62,
Hip1R, Bdnf, Drd3, Uchl1) that likely predominates over
risk-enhancing eﬀects (Mccc1, Gstm1, Calb1) (Figures 1 and
2), although not speciﬁc to the nigrostriatum.
In the MPTP model of PD, however, ﬂuoxetine actually
reduced mouse survival [68]. Whether this is unique to this
model or will generalize across PD models remains to be
determined.
3.25. Sertraline. In rats treated for 21 days, sertraline
upregulated BDNF mRNA expression [72], consistent with
a reduction in PD risk.
3.26. Paroxetine. Paroxetine administered for 21 days upreg-
ulated Bdnf expression [80], consistent with a lower risk for
PD.
3.27.Escitalopram. Inpatientswithdepression,escitalopram
treatment for 12 weeks increased leukocyte BDNF mRNA
expression, correlating with serum BDNF level [81]a n d
suggestive of reduced risk for PD.
3.28. Venlafaxine. Venlafaxine upregulated Bdnf expression
in rats treated for 21 days [71], suggesting a lowering of risk
for PD.
3.29. Duloxetine. In rats treated for 21 days, duloxetine
upregulated BDNF mRNA [82, 83], suggestive of a lower risk
for developing PD.
3.30. Bupropion. Chronic bupropion downregulated hip-
pocampal expression of Bdnf [75], consistent with an
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3.31. Diazepam. Decreased cytochrome c release after treat-
ment with diazepam in neurons exposed to t-butyl-hydroxy-
peroxide [84] has been replicated across models and suggests
a dose-dependent neuroprotective reduced risk of PD pro-
gression. However, higher doses have promoted apoptosis
in other models (see [3] tables published online on journal
website).
3.32.Dextromethorphan-QuinidineCombination. Replicated
ﬁndings in both MPTP and neuroinﬂammatory LPS models
of PD for dextromethorphan include decreased midbrain
dopaminergic neuron degeneration in rat mesencephalic cell
culture [85, 86] and protection of dopamine concentration,
dopamine neurons, and locomotor activity in mice [87].
In MPTP mice, dextromethorphan protected dopamine
neurons [87, 88], dopamine concentrations [87], and loco-
motor activity [87] and reduced glutamatergic excitotox-
icity on dopamine neurons [89] .Ap r e v i o u ss t u d yh a d
not demonstrated protection of dopamine concentrations
in this model [89]. Dextromethorphan also protected
dopamine concentrations in mice treated with both MPTP
and diethyldithiocarbamate [89]. In the methamphetamine
mousemodelofPD,dextromethorphanprotecteddopamine
neurons and prevented microglial activation [90]. Finally,
in the mouse neuroinﬂammatory LPS model of PD, dex-
tromethorphan protected dopamine neurons, dopamine
concentrations, and locomotor activity [87].
Similarly, replicated ﬁndings for the dextromethor-
phan metabolite 3-hydroxymorphinan (3-OHM) include
decreased dopamine neurotoxicity in rat mesencephalic
cell culture [87, 91] and protection of dopamine neurons,
dopamine concentrations, and locomotor activity [87]i n
MPTP and LPS mouse models. 3-OHM was even more
potently protective than dextromethorphan in both models,
an eﬀect that was mediated by enhanced astroglial neu-
rotrophic eﬀects and attenuated microglial activation [87].
Dextromethorphan and its 3-OHM metabolite may
protect dopaminergic neurons by decreasing neuroinﬂam-
mation related to microglial activation with its attendant
increases in ROS, reactive nitrogen species, and TNF-α,
and also by increasing astrocytic neurotrophic support
[85–88, 90, 91]( Figure 1). Additionally, dextromethorphan
may protect dopaminergic neurons by blocking glutamate
excitotoxicity [89]( Figure 2). Furthermore, the 3-hydroxy
metabolite has been found to increase histone H3 acetylation
(like valproate [55]) and neurotrophins including GDNF
and several others (like valproate (see Valproate section) and
antidepressants [4]) [87]( Figure 1). GDNF and BDNF have
demonstrated neuroprotection of nigrostriatal neurons in
several PD models, with GDNF being even more potent than
BDNF [4].
Although there were no transcriptomic data available
for dextromethorphan/quinidine, it is interesting to con-
sider whether dextromethorphan/quinidine is inadvisable
in GSTM1 null genotype patients, since this genotype is
associated with PD risk in the context of CYP2D6 poor
metabolizer status, and quinidine inhibits CYP2D6. This
same concern might also apply to other CYP2D6 inhibitors,
including the psychotropics haloperidol, ﬂuoxetine, paroxe-
tine, duloxetine, and bupropion.
3.33. Neuroprotective Clinical Trials. Several studies have
attempted to look at markers that can potentially ascertain
neuroprotective disease-modifying outcomes. These include
clinical trials of ropinirole, pramipexole, and dextromethor-
phan. Results have been inconclusive to date.
Dopamine agonists constitute ﬁrst-line neuropsychiatric
treatments for apathy and are a mainstay of treatment
for PD. Several double-blind parallel group clinical tri-
als have considered course-of-illness slope divergence to
ascertain neuroprotective properties in PD. These studies
also employed positron emission tomography (PET) and
include a 5-year multicenter study of 288 patients with
early PD randomized to either ropinirole or L-DOPA [92],
the REAL-PET 2-year multicenter trial in 186 patients
with PD randomized to ropinirole or L-DOPA [93, 94], a
study of 45 patients randomized to ropinirole or L-DOPA
[95], and the CALM-PD 2-year multicenter trial in 301
patients with PD randomized to either pramipexole-plus-
placebo “L-DOPA” or L-DOPA-plus-placebo “pramipex-
ole” [96]. The ropinirole study involving 288 patients
found less dyskinesia with ropinirole but no diﬀerence
in clinical markers of PD progression [92], and it is not
clear that dyskinesia can be considered as a marker of
PD pathobiological progression. The ropinirole trial in 45
patients revealed no signiﬁcant diﬀerences between ropini-
role and L-DOPA in terms of 18F-dopa uptake deterio-
ration (13% in 28 versus 18% in 9 patients) at 2 years
compared to baseline [95]. The CALM-PD study showed
less dopaminergic motor complications with pramipexole
but greater UPDRS Parkinson scale improvement with L-
DOPA or L-DOPA-plus-placebo “pramipexole” [96], yet
neuroprotective conclusions are not possible because of
uncertain dose equivalence between the two study arms
and other limitations. Imaging markers in the REAL-
PD investigation revealed slower putamenal (18)F-DOPA
(dopaminergic presynaptic terminal marker) signal decline
with ropinirole [93, 94] while the CALM-PD study demon-
strated reduced β-CIT (dopamine transporter marker)
decrement with pramipexole [97]; however alternative phar-
macological explanations [98, 99] and other limitations
preventing neuroprotective conclusions for the REAL-PET
[98, 100] and CALM-PD [99, 101]s t u d i e sh a v eb e e n
detailed.
Dextromethorphan combined with quinidine is a new
FDA-approved treatment for pseudobulbar aﬀect. In small
clinical trials, dextromethorphan (alone, without quini-
dine) has improved PD signs in two studies [102, 103]
and improved dyskinesia and oﬀ time in two oth-
ers [104, 105], although PD signs did not improve
in another study employing a lower dose [106]. None
of these studies were designed to assess neuroprotec-
tion.
Hence, currently, there is no conclusive clinical evidence
of disease-modifying neuroprotection for psychotropics
although the clinical trial literature in PD is miniscule.10 Parkinson’s Disease
Table 1: Preclinical eﬀects of psychotropics on PD pathobiology.
Gene Protein Psome Cmplx Mt ROS Apop Inﬂam Trophins Animal














Lithium 0 +tau, αSyn +
Carbamazepine +















Dextromethorphan + + +
The eﬀect of psychotropics on PD pathobiology is indicated by a “+” indicating actions consistent with reducing PD risks of onset (gene transcription eﬀects)
or progression (other actions). “−” represents actions that are consistent with enhancing risks of onset or progression. “0” indicates neutral risk: Psome:
proteasome; Cmplx: mitochondrial respiratory chain complexes; Mt: mitochondrion, ROS: reactive oxygen species, Apop: apoptosis, Inﬂam: inﬂammation.
4. Conclusion
Preclinical ﬁndings for the speciﬁc drugs are summarized in
Table 1. Transcriptional eﬀects are subject to the caveats
described below. MAPT, GBA, BDNF, and DRD2 genes
have the clearest relations to PD risk based on knockout
models, null alleles, mutation severity correlations, and
haplotype analysis. MAPT, GBA, MCCC1, CCDC62, and
HIP1R are most strongly linked to PD in risk association
studies. These data indicate that downregulation of MAPT
and upregulation of GBA, CCDC62, HIP1R, and perhaps
BDNF and DRD2 may reduce PD risk, reﬂected in Table 1,
whereas the eﬀects of transcription regulation of the other
genesonPDriskaremoretentative.Otherpreclinicalﬁnding
caveats are detailed below.
The ﬁndings above provide an index of the neuro-
protective potential of psychotropics in PD. Fluoxetine
had salutary transcriptional eﬀects on 7 of the 10 risk
genes studied although its eﬀect on posttranscriptional
events is wanting, and it shortened mouse survival in an
MPTP model. Drugs with multiple actions that may confer
disease-modifying neuroprotection include dextromethor-
phan, valproate, lithium, and pramipexole. These drugs have
neuroprotective eﬀects on αSyn, except that the HDACI
dextromethorphan lacked direct data for this protein, and
lithium had neuroprotective eﬀects on both αSyn and tauParkinson’s Disease 11
protein. One potential therapeutic strategy that might be
tested in animal models and humans is the combination of
valproate with dextromethorphan in attempting to thera-
peutically modulate H3 HDAC, GSK-3, αSyn, ROS, apop-
tosis, and trophic factors. Desipramine (transcriptional and
antiapoptotic properties) and escitalopram (transcriptional
and trophic attributes) might also be worth considering.
Ingeneral,mostdrugsotherthanbupropionandlithium
had beneﬁcial transcriptional eﬀects. This beneﬁt would not
necessarily extend to patients with certain gene variants or
mutations, where these transcription eﬀects might actually
increase PD risk. Most antipsychotics inhibited Complex I,
which is already robustly inhibited in PD. Only pramipexole,
valproate, and dextromethorphan demonstrated replicated
attenuation of ROS while only valproate, desipramine, and
nortriptyline showed consistent replicated antiapoptotic
activity, although desipramine curiously shortened survival
in the MPTP mouse. Whether this result will be obtain-
ed in other PD models remains to be elucidated. Pramipex-
ole, valproate, and dextromethorphan have shown replicated
protective eﬀects in LPS inﬂammatory models, although
anti-inﬂammatory mechanisms await replication while a
neurotrophicmechanismhasbeendocumented[59].Prami-
pexole, ropinirole, and valproate have demonstrated repli-
cated increases in both BDNF and GDNF whereas esci-
talopram increases BDNF and dextromethorphan increases
GDNF.
Enthusiasm for applying the transcriptional results must
betemperedbylimitationsincludingvariablePD-riskassoci-
ations of these genes in diﬀerent populations, changing gene
deﬁnitions and gene risk rankings over time, variable eﬀects
dependingontreatmentdurations,brainregion,andstageof
illness, multiple transcriptional eﬀects of drugs with some-
times contradictory risk eﬀects (e.g., ﬂuoxetine), rodent-hu-
man translational issues, an incomplete understanding of
gene roles in PD pathogenesis, and the uncertainty of how
much of the variance in clinical neuroprotection might be
accounted for by transcriptional eﬀects. The eﬀects of psy-
chotropics on the expression of these genes should now be
studied using RT-PCR, particularly in the substantia nigra
and striatum.
There are several caveats in interpreting how well the
replicated ﬁndings can generalize to and predict clinical
translation. These include limitations inherent to a literature
review, reporting biases, uneven and unsystematic drug
investigation across the various actions of interest, varying
predictive validities of PD animal models, and varying drug
eﬀects that can depend on dose, treatment duration, apopto-
gen, neurotoxin, additional disease-modifying mechanisms
of action, and stage of illness. A given psychotropic can pos-
sess plural neuroprotective and prodegenerative eﬀects and
can act simultaneously as both friend and foe, depending on
the relative weights of these eﬀects. Additionally, increases in
αSyn alone can be either neuroprotective or prodegenerative,
depending upon context. An increase in αSyn can lead to
proteasomal inhibition, apoptosis, and inclusion formations
including Lewy bodies, pathological tau, and Aβ,a n dy e ta
rise in αSyn can also eﬀect a neuroprotective response. It
appears that monoubiquitylation of αSyn with subsequent
translocation to the nucleus may engender apoptosis, in
contrast to an otherwise neuroprotective rise in non-
monoubiquitylated αSyn [57]. In this regard, evidence that
valproate decreased αSyn monoubiquitylation and nuclear
translocationinboththesubstantianigraandstriatumofthe
rotenone rat is tantalizing [57].
At present, no disease-modifying neuroprotective agents
have been conclusively demonstrated to be eﬀective in hu-
man clinical trials. These studies have relied on a diﬀerence
in slope deterioration between treatments to measure pro-
gression, rather than the use of neuroprotective paradigms.
Clinical trials employing delayed-start or randomized-
withdrawaldesigns[107]areneededtoresolvetheneuropro-
tectivedisease-modifyingeﬃcacyofropinirole,pramipexole,
and dextromethorphan in PD. These randomized designs
assess disease-modifying eﬀects by comparing two active
treatment arms to each other, with the comparator arm
receiving placebo for a protracted period followed by active
treatment initiation after a delayed period (delayed start), or
a switch from active treatment to placebo in the comparator
arm substantially before the continued treatment arm is
completed (randomized withdrawal). In this way, diﬀerences
inoutcomeasafunctionofdiﬀeringtreatmentdurationscan
be assessed. Similarly, studies should be undertaken for the
other promising psychotropics that exhibit salutary eﬀects in
animal models and have replicated in vitro ﬁndings. It will
be interesting to learn the results of neuroprotective trials for
these commonly used treatments in patients with PD.
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